Abbott To Pay $1.6B To Settle Depakote Allegations

Law360, Chicago (May 7, 2012, 4:10 PM EDT) -- Abbott Laboratories Inc. pled guilty to drug misbranding and agreed to pay $1.6 billion on Monday to resolve state and federal investigations into its off-label marketing of the anti-seizure drug Depakote and related kickback and false claims allegations.

The U.S. Department of Justice said the pharmaceutical giant will pay a criminal fine and forfeiture of $700 million plus civil settlements with the federal government and states totaling $800 million. Abbott said it will also shell out $100 million to states to resolve related consumer protection claims,...
To view the full article, register now.